Skip to content

Study · Case report or series · n = 1 · 2020

1 result

Gastroparesis With the Initiation of Liraglutide: A Case Report.

Almustanyir S, Alhabeeb H, AlHusseini N, Al Thow M

Cureus28 Nov 2020Cited by 6 (Europe PMC)

PMID33403167 (opens in a new tab)PMCIDPMC7773310 (opens in a new tab)DOI10.7759/cureus.11735 (opens in a new tab)PepBankPUB-33403167
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Gastroparesis is a syndrome that is manifested by gastrointestinal symptoms and delayed gastric emptying without evidence of mechanical obstruction. Herein, we present the case of an 18-year-old diabetic female patient who developed clinical features suggestive of gastroparesis after initial doses of liraglutide. Although rare, drug-induced gastroparesis should be contemplated in diabetic patients with a history of recent commencement of liraglutide, particularly at higher doses. Management of drug-induced gastroparesis is largely symptomatic.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In an 18-year-old diabetic female patient, clinical features suggestive of gastroparesis developed after the initial doses of liraglutide.

    In plain wordsIn one young woman with diabetes, signs of slow stomach emptying appeared after the first doses of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableGastroparesis after initial liraglutide doses
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Herein, we present the case of an 18-year-old diabetic female patient who developed clinical features suggestive of gastroparesis after initial doses of liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT06154486

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Hospital Israelita Albert Einsteinn = 3019 Jun 2023 to 22 Aug 2023

Pneumonia, Aspiration · Anesthesia

Trial pageClinicalTrials.govUpdated 4 Dec 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.